These data reinforce the well-established long-term safety profile of Dupixent in moderate-to-severe atopic dermatitis.... Oct 29
... Oct 29
Cipla will be responsible for the marketing and distribution of the SARS CoV-2-IgG antibody detection ELISA that will be manufactured by KARWA Ltd.... Oct 28
... Oct 27
The Bristol Myers Squibb–Pfizer Alliance, with the support of leading advocacy organizations and medical societies, announces the launch of the No Time to Wait ... Oct 26
New late-breaking data showing additional improvements in disease severity and extent at the microscopic level ... Oct 26
Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed across the world... Oct 24
Albuterol is a bronchodilator and it helps open up the airways in your lungs to make it easier to breathe. ... Oct 23
... Oct 23
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Topical Solution, 5%, of Anacor Pharmaceuticals, Inc.... Oct 22
Fenofibrate Capsules USP, 67 mg, 134 mg and 200 mg have an estimated market size of US$ 17 million for twelve months ending June 2020 ... Oct 21
ViiV Healthcare, today announced the positive findings of a pooled analysis of COVID-19-related impacts across the investigational long-acting cabotegravir and rilpivirine clinical ... Oct 21
Cipla Limited today announced that it has launched generic Nintedanib for the treatment of Idiopathic Pulmonary Fibrosis ... Oct 21
Zydus Cadila has received final approval from the USFDA to market Solifenacin Succinate Tablets, in the strengths of 5 mg and 10 mg... Oct 21
Umifenovir did not show superior clinical outcomes when added to Favipiravir treatment. The trial did not meet key end-points ... Oct 21
Pneumococcal disease in adults is on the rise globally, in part driven by disease-causing serotypes not targeted by the currently available pneumococcal conjugate vaccine... Oct 21
... Oct 20
Results from CheckMate -9ER recently presented during a Presidential Symposium at the European Society for Medical Oncology Virtual Congress... Oct 19
Avalglucosidase alfa is an investigational enzyme replacement therapy, which, if approved, would offer a potential new standard of care for patients with Pompe disease... Oct 02
-Advertisements-